3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Key Points

• Three small-cap biotechs, Kodiak Sciences, Capricor Therapeutics, and Invivyd, face binary clinical trial or FDA decisions before the end of 2026.
• Kodiak's Phase 3 DAYBREAK results for wet AMD, due between September and December 2026, could ease balance sheet concerns after widening losses.
• Capricor awaits a delayed Nov. 22, 2026, FDA decision on Deramiocel, while Invivyd anticipates Phase 3 DECLARATION results for its COVID-19 antibody VYD2311.

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.

When that moment arrives, there's rarely a middle ground: a positive result can send shares sharply higher and validate years of spending, while a miss can wipe out most of the market cap overnight. That's what makes these "binary catalysts" so important to track, and so risky to hold through.

Below are three small-cap biotechs facing exactly that kind of moment before the end of 2026. Each has a different disease, a different drug, and a different timeline, but all three share the same setup: one event, largely beyond the company's control, that could reset the stock's trajectory with a single announcement.

Kodiak Sciences: A Wet AMD Verdict That Could Reset the Balance Sheet

Kodiak Sciences NASDAQ: KOD is a clinical-stage biopharmaceutical company focused on the development of novel therapies for retinal diseases. What’s driving interest in KOD in late 2026 is the expected results from the company’s Phase 3 DAYBREAK study.

DAYBREAK is testing two of Kodiak's drug candidates, Zenkuda and KSI-501, in patients who have never been treated for wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss in which abnormal blood vessels leak fluid behind the retina.

Because each drug is being evaluated separately against aflibercept, the current standard of care, DAYBREAK is effectively two readouts packaged into one headline event. Both comparisons test whether Kodiak's candidate can match aflibercept's vision and safety outcomes while requiring fewer eye injections over the course of a year, with roughly 690 patients enrolled across the two.

It’s not being hyperbolic to say that these clinical trial results, which are due out between September and December 2026, represent a make-or-break moment for KOD shareholders. Drug development is expensive, and Kodiak’s net loss in Q2 2026 widened to $65.6 million, which was more than the $54.3 million loss in the prior year.

That’s coming at a time when the company reported significant year-over-year reductions in working capital and stockholder equity. Kodiak ended the quarter with $125.9 million in cash and equivalents, which management says will cover operations into 2027.

Positive DAYBREAK results would mitigate balance sheet concerns. Analysts are bullish about those results. The analyst forecasts on MarketBeat have a consensus Moderate Buy rating with a $48.14 price target, representing a 48% gain from recent prices.

Capricor Therapeutics: A Delayed FDA Decision Still Looms Large

Capricor Therapeutics NASDAQ: CAPR is another clinical-stage biotech. The company’s focus is on developing cell and exosome-based therapeutics for cardiovascular and rare diseases.

Capricor’s leading drug candidate is Deramiocel for the treatment of Duchenne Muscular Dystrophy. The drug is under review by the U.S. Food and Drug Administration, which has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel from Aug. 22 to Nov. 22, 2026.

This came after Capricor submitted additional two-year follow-up data from its pivotal HOPE-3 study supporting a narrower, upper-limb-focused indication. Regulators classified the new data as a major amendment, which is what triggered the three-month delay, but the underlying decision itself hasn't changed: it's simply been pushed to late November.

The consensus price target of analysts tracked by MarketBeat for CAPR is $29.15, which would be over 230% upside relative to recent prices.

Invivyd: Betting on a Next-Generation COVID Shield

Invivyd NASDAQ: IVVD focuses on discovering, developing, and commercializing antibody-based solutions for infectious diseases. What makes Invivyd different from the other two names in this article is that the company has a commercially available product, PEMGARDA, which is a long-acting monoclonal antibody for pre-exposure prophylaxis of COVID-19. The drug targets immunocompromised patients whose bodies don’t mount an adequate response to vaccination.

The immediate catalyst for Invivyd is the DECLARATION study. This is a pivotal Phase 3 trial for VYD2311, essentially a next-generation, longer-acting successor to PEMGARDA aimed at the same immunocompromised population.

The trial has three arms—a single dose of VYD2311, a multi-dose regimen, and a placebo—and has already earned FDA Fast Track designation. Enrollment is complete, and the study is now approaching its planned analysis, with Invivyd holding a dedicated investor call once results are in rather than folding the news into a routine earnings report.

Success would provide the company with an expanded label for treating COVID-19. The company has other pipeline candidates in earlier clinical trial phases that could position it for a range of other conditions, including measles, mumps, rubella, and Lyme disease.

IVVD is a true penny stock, trading for just 81 cents per share as of this writing. However, analysts have a consensus price target of $8. That price target is supported by HC Wainwright and Cantor Fitzgerald, both of which have reiterated Buy or equivalent ratings since the company’s Q2 2026 earnings report in August.